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Strengths and limitations of this study
 ► This is one of the largest qualitative studies in the UK 
to explore views on the timing of deinfibulation and 
NHS female genital mutilation (FGM) care provision 
with a range of key stakeholders including survivors, 
male partners and healthcare professionals (HCPs).
 ► This cross-cultural and cross-language study will 
allow us to hear narratives from a range of FGM-
affected communities across the UK.
 ► This qualitative study is informed by the Sound of 
Silence conceptual framework.
 ► The study is supported by an active FGM survivor 
group, a charity partner, a number of NHS trusts and 
third sector organisations.
 ► Recruitment, data collection and interpretation 
may be challenging due to the cross-cultural and 
cross-language nature of the study.
AbStrACt
Introduction Female genital mutilation (FGM) is a 
significant global health concern and is likely to become 
an increasingly important healthcare challenge in 
destination countries such as the UK owing to rising levels 
of migration from FGM-affected countries. Currently, there 
is no consensus on the optimal timing of deinfibulation 
(opening) surgery for women who have experienced type 3 
FGM and care provision remains suboptimal in the UK. This 
qualitative study aims to explore the views of survivors, 
male partners and healthcare professionals (HCPs) on the 
timing of deinfibulation and delivery of NHS FGM services.
Methods and analysis A qualitative study, informed 
by the Sound of Silence conceptual framework, will 
be undertaken via two work packages (WPs). WP1 will 
explore views on timing preferences for deinfibulation 
and NHS FGM services through interviews and discussion 
groups with FGM survivors (n~50), male partners (n~10) 
and HCPs (n~50). WP2 will use established techniques 
via two workshops (community (n~20–25 participants) 
and national stakeholder (n~30–35 participants)) to 
synthesise qualitative research findings and inform best 
practice and policy recommendations around the timing 
of deinfibulation and NHS FGM care provision. Supported 
by trained interpreters, data collection will be audio 
recorded and transcribed. Data will be analysed using the 
framework method to facilitate a systematic mapping and 
exploration of qualitative data from multiple sources.
Ethics and dissemination The study has received ethical 
approval from the North West Greater Manchester East 
Research Ethics Committee (18/NW/0498). The outputs for 
this study will be recommendations for best practice and 
policy around FGM care provision that reflects the views 
and preferences of key stakeholders. The findings will be 
disseminated via conference presentations, peer-reviewed 
publications, patient groups, third sector organisations and 
social media.
trial registration number ISRCTN 14710507.
IntroduCtIon
Female genital mutilation or cutting (here-
after referred to as FGM) is an increasingly 
global issue owing to international mobility 
and migration.1 The practice of FGM has 
been performed for millennia2 and continues 
to be prevalent in some countries in Sub-Sa-
haran Africa, Asia and the Middle East.3 An 
estimated 200 million women and girls live 
with FGM globally.1 In the UK, FGM is iden-
tified increasingly among migrants from 
FGM-affected countries, with 137 000 women 
and girls reported as currently living with 
the consequences.4 Between April 2015 and 
December 2017, 15 390 women and girls 
presented to NHS services where FGM was 
identified as a relevant condition and/or 
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treated.5 The annual cost of NHS care for FGM survivors 
is estimated at £100 million.6
FGM involves the partial or complete removal of, or 
injury to, the external female genitalia for non-medical 
reasons.7 The WHO joint statement has classified FGM 
into four main types (types 1–4), with a further seven 
subtypes (types 1a,b; 2a–c; 3a,b) identified to capture 
more closely the variation in practices.8 9 Generally, the 
extent of genital tissue cut increases from type 1 to type 
3, with type 3 (infibulation) being the most extensive and 
often requiring deinfibulation7 (a surgical procedure to 
release the narrowed vaginal introitus). There are imme-
diate and lifelong health, obstetric, sexual functioning, 
psychosocial and economic impacts associated with 
FGM.4 10–17 The risks of adverse outcomes appears to be 
greater the more extensive the FGM,15 with 9 in 10 type 
3 FGM survivors reporting complications.18 The conse-
quences of type 3 FGM may lead to loss of life and reduced 
quality of life.10 19 The WHO reports20 that deinfibula-
tion is associated with improved health and well-being, 
as well as, allowing sexual intercourse and childbirth, 
although there is limited direct evidence to support this 
statement. A recent systematic review found no evidence 
that deinfibulation improved urological complications.21 
There is however a case to be made that deinfibulation 
is associated with improved gynaecologic and obstetric 
outcomes, although this is based on low-quality observa-
tional evidence.22
There has been slow progress in the development 
of evidence-based care to improve health outcomes 
for FGM survivors, in particular, around the optimal 
timing of deinfibulation.20 23 24 Deinfibulation can be 
undertaken outside of or during pregnancy24; however, 
there is considerable variation within and between clin-
ical recommendations for when deinfibulation should 
occur.23 For example, Royal College of Obstetricians and 
Gynaecologists (RCOG) guidelines25 recommend that 
deinfibulation should be offered prior to pregnancy and 
preferably before first sexual intercourse. These guide-
lines also state that deinfibulation can be performed 
antenatally, in the first stage of labour, at delivery or 
perioperatively after a caesarean section. Royal College 
of Nursing (RCN) FGM guidance26 does not provide a 
clear indication on the optimal timing of deinfibulation, 
with one statement indicating that the procedure is best 
performed when not pregnant and another that deinfib-
ulation is best undertaken before or at least within the 
second trimester of pregnancy. WHO guidelines on the 
management of FGM20 recommend either antepartum or 
intrapartum deinfibulation with a suggestion that timing 
should be based on wider contextual factors including 
patient preference, access to healthcare facilities, place of 
delivery and the skill level of the healthcare professional 
(HCP). In addition to a lack of consensus about when 
deinfibulation should be performed, there is also debate 
about whether timing affects outcomes, with some studies 
suggesting that obstetric risks increase the later deinfib-
ulation is undertaken.27 28 However, these findings were 
not substantiated in a recent systemic review of low-quality 
observational evidence comparing childbirth outcomes 
between antepartum and intrapartum deinfibulation.24
A gap analysis of current FGM research has suggested 
that there is an urgent need for well-designed research 
to inform evidence-based guidelines and to improve the 
healthcare of women and girls with FGM.23 A recent qual-
itative systematic review highlighted that it is important 
for future research to focus on care-seeking and decision 
making around the timing of deinfibulation.29 To date, in 
the UK, there has been one qualitative study that directly 
explored women’s experiences of deinfibulation30 and no 
studies exploring the views of men and HCPs. With no 
clear consensus on the optimal timing of deinfibulation 
for type 3 FGM survivors,20 23 24 there is a specific need to 
focus on exploring preferences, involving a diverse range 
of FGM survivors, their male partners and HCPs, across 
multiple centres.23 31 Such research may help to inform 
the strategic planning and development of cost-effective, 
culturally acceptable NHS services, leading to improved 
outcomes for women and their families and help other 
organisations (eg, third sector organisations) plan for 
improved support for FGM survivors and their families. 
This paper presents the protocol for the FGM Sister Study.
Aims and objectives
The aim of the FGM Sister Study is to explore and under-
stand the views of FGM survivors, male partners and HCPs 
on the timing of deinfibulation and how NHS services 
can best be delivered to meet the needs of FGM survivors 
and their families. We will address this overarching aim 
via two work packages (WPs). The aims and objectives of 
each WP are presented in table 1.
MEthodS And AnAlySIS
Study design and conceptual framework
The FGM Sister Study is a qualitative study, informed by 
the Sound of ‘Silence’ (‘Silences’) conceptual framework.32 
The ‘Silences’ framework is underpinned by broader 
theoretical approaches with a worldview that accepts that 
reality (or ‘truth’) is not objective, rather the social world 
is influenced by people in a particular society at a partic-
ular point in time.33 ‘Silences’ define areas of research 
and experiences that are little researched, understood or 
not heard34 and are useful for researching sensitive issues 
and/or the healthcare needs and perspectives of margin-
alised populations.32 Within the context of this study, 
although FGM is a contemporary issue that has increas-
ingly become the subject of political and media interest, 
it remains a sensitive issue prevalent among marginalised 
populations and one that is under-researched. ‘Silences’ 
elucidates and underpins the research using a four-stage 
approach: (1) working in Silences, (2) hearing Silences, 
(3) voicing Silences and (4) working with Silences. There 
is an additional fifth stage, (5) planning for Silences, that 
is not incorporated into the core four-stage model but will 
be used to help inform service delivery action planning 
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Table 1 Summary of FGM Sister Study aims and objectives by work package
Work package 1 Work package 2
Aim: To qualitatively explore and understand the timing 
preferences for deinfibulation and how NHS FGM services 
could be improved for type 3 FGM survivors (WP1a), their 
male partners (WP1b) and HCPs (WP1c).
Aim: To use established techniques with survivors (WP2a) and 
stakeholders (WP2b) to synthesise the qualitative research 
findings, inform best practice and policy recommendations 
around the timing of deinfibulation and FGM care provision and 
identify future actions.
  Objectives:
1. to explore knowledge, awareness and understanding of 
FGM and deinfibulation (WP1a,b,c)
2. to elicit views on preferences for the timing of 
deinfibulation and the rationale for these (WP1a,b,c)
3. to explore perspectives on the decision making process 
around deinfibulation (WP1a,b)
4. to explore knowledge, awareness and experiences of FGM 
services and support (WP1a,b,c)
5. to understand the enablers, motivators and barriers to 
FGM care seeking behaviours (WP1a,b)
6. to explore how HCPs describe, explain and reason about 
their care provision for FGM survivors and their families 
(WP1c)
7. to understand how FGM care provision could be improved 
to best meet the needs of FGM survivors, their families 
and HCPs who support them in their local context 
(WP1a,b,c)
  Objectives:
1. to explore views and reflections on the trustworthiness of 
our interpretation of the data and the conclusions drawn 
(WP2a,b)
2. to establish if there is consensus about the optimal timing of 
deinfibulation (WP2a,b)
3. to identify the key recommendations to inform NHS FGM 
care provision (WP2a,b)
4. to explore the facilitators and barriers to implementation of 
changes to NHS FGM care provision (WP2b)
5. to explore views on the requirements for future FGM 
research (eg, RCTs) (WP2b)
FGM, female genital mutilation; HCPs, healthcare professionals; RCT, randomised clinical trial; WP, work package.
and future recommendations for research, policy and 
practice
Study setting and timing
The study will be undertaken with FGM survivors (WP1a 
and WP2a) and male partners (WP1b) in three high FGM 
prevalence areas of England (Birmingham, Manchester 
and London) and with HCPs (WP1c) and key stakeholders 
(WP2b) across the UK including areas of high and low 
FGM prevalence. Data collection for WP1 commenced in 
September 2018, and initial analyses are planned to be 
completed ahead of the start of WP2 in November 2019. 
Synthesis of the results of WP1 and WP2 and final recom-
mendations are planned to be completed by May 2020.
Eligibility
WPs 1a, 1b and 2a
Women who have experienced FGM and male partners 
of women who have experienced FGM will be eligible to 
participate if they are aged 18 years or over, are resident 
in the UK, speak fluent English, Somali, Arabic or French 
and are willing and able to provide voluntary informed 
consent (written, electronically completed or verbally). 
We will exclude anyone where their clinician, support 
worker or the researcher judges that their distress relating 
to FGM may influence their ability to provide voluntary 
informed consent. Additionally, we will not snowball 
recruitment of a male partner where the participating 
FGM survivor does not consent to their participation.
Work package 1c
HCPs (including but not limited to general practitioners, 
practice nurses, midwives, obstetrics and gynaecology 
clinicians, genitourinary clinicians, health visitors and 
sexual health specialists) will be eligible to participate 
if they are aged 18 years or over, speak fluent English, 
are willing and able to provide written, electronically 
completed or (audio recorded) verbal informed consent 
and are currently or have recently been involved (within 
the last 5 years) in the delivery of care to FGM survivors 
and their families in the UK.
Work package 2b
Key FGM stakeholders including (but not limited to) 
HCPs (see list in WP1c eligibility), policy makers, FGM 
specialist researchers/academics, health economists, 
commissioners and representatives from third sector 
organisations (eg, charities and advocacy groups) will 
be eligible to participate if they are aged 18 years and 
over, speak fluent English, are willing and able to provide 
written, electronically completed or (audio recorded) 
verbal informed consent and are currently or have 
recently been involved (within the last 5 years) in some 
aspect of service and/or care provision to FGM survivors 
and their families in the UK.
Sampling and recruitment
Work package 1a
Four groups of pregnant and non-pregnant FGM survi-
vors will be purposively sampled35 including those: (1) 
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who have not had deinfibulation, (2) who have had 
deinfibulation for health and/or personal reasons, (3) 
who had deinfibulation antenatally and (4) who had 
deinfibulation during labour/at the point of delivery 
(intrapartum). Within these groups, we will try to ensure 
that we have maximum variation and diversity of views 
by including women from a range of FGM-affected 
communities (eg, Somali, Yemeni, Eritrean), locations, 
ages and education levels.36 Women will be recruited via 
multiple pathways including, for example, their HCP; 
advertising within FGM clinics, community settings and 
on social media, culturally sensitive snowballing37 from 
women approached to participate and FGM community 
groups/third sector organisations. Multiple NHS trusts 
and third sector organisations (eg, charities and advocacy 
groups) will support the study. Relevant staff at partici-
pant identification sites will be trained by the research 
team (via a site initiation visit or equivalent) to approach 
potential FGM survivors. Women will be approached, in 
the first instance, by a member of their usual care team 
(eg, midwife) or by a trusted advocate in a third sector 
organisation. Recruiters will be asked to briefly screen 
for eligibility and introduce the study. All documents to 
support participant identification and recruitment will 
be available in English, French, Somali and Arabic. If the 
woman responds positively, she will be asked to complete 
and sign a contact details form giving permission to be 
contacted by the research team. A researcher will then 
contact the woman to check her eligibility, discuss the 
study further, answer any questions she might have and 
arrange a mutually convenient time and location for the 
interview or to let her know the times and locations of 
discussion groups. At the end of the interview/discussion 
group, women will be asked discretely if their partner may 
wish to participate in the study. If she responds positively, 
then contact details of the research team will be left or 
if the man is present, then the recruitment and consent 
process will be initiated.
Work package 1b
Men will be identified via participants from WP1a, via 
support of local community groups and third sector 
organisations and via social media.
Work package 1c
HCPs will be purposively recruited35 from across a range 
of groups including (but not limited to) general practi-
tioners, practice nurses, midwives, obstetrics and gynae-
cology clinicians, genitourinary clinicians, health visitors 
and sexual health specialists. HCPs across the UK will be 
identified via multiple pathways including, for example 
via: FGM service listings; contacting NHS trusts with 
maternity services in low FGM prevalence areas directly; 
the study team’s FGM networks; advertising the study via 
electronic communications (eg, social media), profes-
sional bodies and membership societies; and snowballing 
from HCPs approached to participate. HCPs who express 
an interest in participating will be screened for eligibility 
by the research team, provided with further study infor-
mation, given time to answer questions and then a 
mutually convenient time and location for the interview 
arranged, or they will be told about the times and loca-
tions of discussion groups.
Work package 2a
FGM survivors who take part in WP1a will be invited to 
participate. If required, recruitment will be supplemented 
via the same pathways as identified in WP1a above.
Work package 2b
HCPs interviewed in WP1c will be invited to participate. 
Other key stakeholders (see list in WP1c and WP2b eligi-
bility) will be identified via the research team’s networks 
and collaborators, social media and knowledge of FGM 
services acquired during the study.
Anticipated sample sizes
WP1 (total n up to 110)
We will seek to recruit:
 ► up to 50 women who are FGM survivors,
 ► up to 10 male partners,
 ► up to 50 HCPs.
WP2 (total n up to 60)
We will seek to recruit:
 ► 20–25 FGM survivors for the community engagement 
event,
 ► 30–35 stakeholders for the national stakeholder event.
Numbers will however remain flexible to ensure that we 
collect sufficiently rich data to answer the research ques-
tions and achieve core analytic saturation.38
data collection
Work package 1
Semistructured interviews have been identified as an 
appropriate data collection method, given that they can 
facilitate an in-depth exploration of participants’ ‘Silent’ 
views39 and are particularly useful in discussions of sensi-
tive or traumatic experiences such as FGM. In addition, 
discussion groups will be used as an alternative data 
collection tool for FGM survivors and male partners, as 
Patient and Public Involvement representatives (here-
after referred to as ‘the survivor group’) felt that women 
and men in some communities may be more willing, 
given the nature of the topic, to participate in a group 
rather than an individual discussion.
Interviews and discussion groups will be conducted 
by a trained qualitative researcher and two researchers 
will be present in all discussion groups. Independent, 
professional interpreters (who have undergone FGM 
training by the research team) will be employed to 
provide real-time oral translation (either face-to-face or 
on the phone) during the interviews/discussion groups 
where there is a language barrier between researcher(s) 
and participant(s). Debriefs between researcher(s) and 
interpreter(s) will be held after interviews/discussion 
groups if interpretation issues are identified. In addition, 
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researchers will keep a research journal throughout the 
data collection period to help to provide reference points 
in the journey to expose ‘Silences’.32
Participants will be given the choice as to whether they 
wish to take part in an interview or a discussion group. If 
they choose to take part in an interview, they will be given 
a choice as to where it takes place, for example, in their 
own home, in a clinic room where they were recruited/
work or via telephone (including Skype or other online 
communication tools). Discussion groups will take place 
in an appropriate location, for example, a community 
venue or clinic. Aligned with ‘Hearing Silences’ (stage 
2 of the ‘Silences’ conceptual framework),32 discussion 
guides for WP1a–c will be informed by a critical reflec-
tion of the FGM evidence base (see online supplemen-
tary files 1–3). These ‘Silences’ will then be heard by and 
discussed within the research team and with the survivor 
group. Semistructured interviews and discussion groups 
will be conducted in a participant-focused manner, 
allowing experiences and views important to participants 
to develop naturally.40 The composition of the partici-
pants in each discussion group will be carefully consid-
ered, taking into account language, the community from 
which they are from, their deinfibulation experience and 
wider demographic characteristics.
Discussion guides will be refined iteratively to ensure 
that all views are captured. Data collection and analysis 
will take place concurrently39 and will continue until 
the research team judge that the data and sample have 
sufficient depth and breadth to address the research 
objectives.38 At (or before) each interview/discussion 
group, participants will be asked to complete a short 
demographic questionnaire to facilitate maximum vari-
ation sampling and provide a description of the sample 
characteristics.
Work package 2
A community engagement event (WP2a) and a national 
stakeholder (WP2b) event will be run by FGM experts at 
Barnardo’s, with support from the wider research team 
and the survivor group. Participants will be shown a 
plain English summary (drafted and discussed with the 
survivor group) in advance. At the start of each event, 
a study overview will be presented. Participants may 
be split into smaller discussion groups facilitated by a 
member of Barnardo’s and supported by a member of 
the research team and/or the survivor group. Discussion 
groups were identified as an appropriate data collec-
tion method, given that they provide an opportunity for 
interaction and communication between participants 
in order to generate data and can provide a permissive 
and empowering environment where participants feel 
comfortable enough to share their views and question 
those of others.41–43 Discussion will focus on participants’ 
reflections of the trustworthiness of our interpretation 
of the data and the conclusions drawn; an exploration of 
‘what has or can change as a result of this study’ (aligned 
with Stage 4 ‘working with Silences’ of the ‘Silences’ 
conceptual framework32) in terms of NHS policy and 
practice and identifying future research to address other 
identified ‘unheard Silences’.32 Recommendations from 
each group will be shared and discussed within the whole 
group to establish if a consensus on the timing of dein-
fibulation can be reached and to identify the next steps 
following study completion.
data analysis
Interviews, discussion groups and events will be audio 
recorded and transcribed using an intelligent transcrip-
tion system (ie, the conversation is transcribed verbatim 
but without unnecessary verbiage or linguistic fillers) 
by a specialist company and subsequently checked for 
quality and anonymised by the research team. Up to six 
transcripts of interpreted interviews will have both the 
English and the second language translated and tran-
scribed. This is to enable the research team to check that 
interpreters are employing content interpretation rather 
than word-for-word translation and to ensure that inter-
preted responses are conducive to and reflect the depth 
of response provided by the participant.
Data analysis will be informed by framework anal-
ysis,44 which provides a systematic and flexible model for 
managing and mapping qualitative data from multiple 
sources. The research team will use a five-stage frame-
work approach45 that captures, but also condenses, 
other framework approaches involving a greater number 
of stages. These five stages include (1) compiling 
(researchers collect data), (2) disassembling (researchers 
become familiar with and organise the data), (3) reas-
sembling (researchers produce matrices to analyse the 
data), (4) interpreting (researchers interpret the data to 
identify key themes, concepts, relationships, etc) and (5) 
concluding (researchers present findings). Each stage of 
the framework approach can be aligned with the stages of 
the Sound of ‘Silence’ conceptual framework to ensure 
relevant synthesis of qualitative methodology and philo-
sophical/conceptual underpinnings that is sensitive to 
the research topic and is appropriate for the research 
study (see online supplementary file 4).
Patient and public involvement
In addition to our co-applicant and Study Steering Group 
(SSG) FGM survivors, a lay group of type 3 FGM survivors, 
with different experiences of deinfibulation, has been 
established. Discussions, where possible, are co-facilitated 
by the chief investigator and our FGM survivor co-ap-
plicant. The survivor group and co-applicant have been 
actively involved in the design of the study and writing of 
the study documentation. For example, the group chose 
the logo and name of the study, have provided critical 
review of all participant facing materials and helped to 
co-produce the discussion guides. In addition, they will 
provide on-going problem solving support, critical review 
of interview transcripts and the research team’s interpre-
tation of data and support dissemination plans.
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EthICS And dISSEMInAtIon
data management, monitoring and oversight
The University of Birmingham is the nominated sponsor 
and data controller for the study. Data management and 
storage will be subject to the UK Data Protection Act 
2018 and will follow relevant University of Birmingham 
policy and procedures. Identifiable data will be securely 
stored and then safely destroyed within 12 months of 
publication of the main results of the study. Anonymised 
data will be securely stored for a minimum of 10 years 
after the publication of the main study results. An inde-
pendently chaired SSG has been convened to oversee the 
study and includes an FGM survivor, academics, FGM-spe-
cialist HCPs and third sector representatives. The SSG 
has agreed the study protocol and will agree any subse-
quent amendments. This group will monitor adherence 
to protocol and participant safety and will ensure that the 
study runs in accordance with the principles of good clin-
ical practice and relevant regulations.
outputs and dissemination
Dissemination is likely to focus on: the findings of the 
qualitative research with FGM survivors and their male 
partners; the qualitative research with HCPs working with 
FGM survivors and their families and the overarching 
policy and practice implications and recommendations 
of the research. The study final report (including a plain 
English summary co-produced with the survivor group) 
will be available through the National Institute for Health 
Research (NIHR) website, published in open access 
peer-reviewed journals and presented at relevant confer-
ences and events.
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